Brain cancer vaccine shows promise in early trial
NCT ID NCT04968366
First seen May 05, 2026 · Last updated May 09, 2026 · Updated 1 time
Summary
This early-phase study tested a personalized vaccine made from a patient's own immune cells combined with standard chemotherapy for newly diagnosed glioblastoma, an aggressive brain cancer. Eleven adults who had surgery to remove most of their tumor received the vaccine plus the drug temozolomide. The main goal was to check safety, and researchers also looked for signs that the vaccine triggered an immune response against the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME OF BRAIN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100730, China
Conditions
Explore the condition pages connected to this study.